Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Debt to Equity (2016 - 2021)

Historic Debt to Equity for Lineage Cell Therapeutics (LCTX) over the last 6 years, with Q1 2021 value amounting to $0.0.

  • Lineage Cell Therapeutics' Debt to Equity changed N/A to $0.0 in Q1 2021 from the same period last year, while for Mar 2021 it was $0.0, marking a year-over-year change of. This contributed to the annual value of $0.01 for FY2020, which is N/A changed from last year.
  • As of Q1 2021, Lineage Cell Therapeutics' Debt to Equity stood at $0.0.
  • In the past 5 years, Lineage Cell Therapeutics' Debt to Equity ranged from a high of $0.01 in Q3 2020 and a low of $0.0 during Q4 2017
  • Over the past 3 years, Lineage Cell Therapeutics' median Debt to Equity value was $0.0 (recorded in 2021), while the average stood at $0.0.
  • Examining YoY changes over the last 5 years, Lineage Cell Therapeutics' Debt to Equity showed a top increase of 7101.49% in 2017 and a maximum decrease of 8808.24% in 2017.
  • Over the past 3 years, Lineage Cell Therapeutics' Debt to Equity (Quarter) stood at $0.0 in 2017, then soared by 4861.33% to $0.01 in 2020, then decreased by 18.25% to $0.0 in 2021.
  • Its last three reported values are $0.0 in Q1 2021, $0.01 for Q4 2020, and $0.01 during Q3 2020.